Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

In English

Författare

  • Anders Waage
  • Peter Gimsing
  • Peter Fayers
  • Niels Abildgaard
  • Lucia Ahlberg
  • Bo Bjorkstrand
  • Kristina Carlson
  • Inger Marie Dahl
  • Karin Forsberg
  • Nina Gulbrandsen
  • Einar Haukas
  • Oyvind Hjertner
  • Martin Hjorth
  • Torbjorn Karlsson
  • Lene Meldgaard Knudsen
  • Johan Lanng Nielsen
  • Olle Linder
  • Ulf-Henrik Mellqvist
  • Ingerid Nesthus
  • Jurgen Rolke
  • Maria Strandberg
  • Jon Hjalmar Sorbo
  • Finn Wisloff
  • Gunnar Juliusson
  • Ingemar Turesson
Visa allt

Summary, in English

In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The dose of thalidomide/placebo was escalated to 400 mg daily until plateau phase and thereafter reduced to 200 mg daily until progression. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the MPT and MP arms, respectively (P < .001). There was no significant difference in progression-free or overall survival, with median survival being 29 months in the MPT arm and 32 months in the MP arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm. Constipation, neuropathy, non-neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the MPT arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, MPT had a significant antimyeloma effect, but this did not translate into improved survival. This trial was registered at www.clinicaltrials.gov as #NCT00218855. (Blood. 2010;116(9):1405-1412)

Publiceringsår

2010

Språk

Engelska

Sidor

1405-1412

Publikation/Tidskrift/Serie

Blood

Volym

116

Issue

9

Dokumenttyp

Artikel i tidskrift

Förlag

American Society of Hematology

Ämne

  • Hematology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1528-0020